<DOC>
	<DOCNO>NCT00544869</DOCNO>
	<brief_summary>To investigate plasma drug level , efficacy , safety 7-day repeated oral administration OPC-41061 15 mg/day ( treatment period 1 ) subsequent 7-day repeat administration OPC-41061 15 mg/day 30 mg/day diuretic effect insufficient ( treatment period 2 ) congestive heart failure ( CHF ) patient extracellular volume expansion despite conventional diuretic therapy .</brief_summary>
	<brief_title>A Study OPC-41061 Subjects With Cardiac-induced Edema ( Congestive Heart Failure )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Edema , Cardiac</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Subjects cardiac edema receive diuretic treatment since 7 day prior commencement study drug administration . 2 . Subjects receive one follow diuretic treatment since 3 day prior commencement study drug administration without change dose dose regimen ( include subject schedule start treatment runin observation period ) . 1 . A loop diuretic daily dosage equivalent 40 mg furosemide 2 . Concomitant administration loop diuretic thiazide diuretic ( dos ) 3 . Concomitant administration loop diuretic antialdosterone drug ( dos ) 3 . CHF patient low limb edema , jugular venous distention , pulmonary congestion due extracellular volume expansion . 4 . Male female subject age 20 85 , inclusive ( time inform consent ) 5 . Subjects able stay study site day start runin observation period completion posttreatment observation 2 ( 7 10 day final study drug administration ) 6 . Subjects capable give informed consent participate study free 1 . Heart failure patient markedly fluctuate symptom 2 . Patients assisted circulation device 3 . Patients follow complication symptom : 1 . Suspected decrease circulatory blood flow ， 2 . Hypertrophic cardiomyopathy ( dilated phase ) ， 3 . Cardiac valve disease significant heart valve stenosis， 4 . Hepatic coma 4 . Patients develop acute myocardial infarction within 30 day prior screen examination 5 . Patients definite diagnosis active myocarditis amyloid cardiomyopathy 6 . Subjects follow complication symptom : 1 . Poorly control diabetes melllitus， 2 . Anuria， 3 . Urination impair due urinary tract stricture , urinary calculus , tumor urinary tract , cause 7 . Subjects follow disease history : 1 . Sustained ventricular tachycardia ventricular fibrillation within 30 day prior screen examination subject without implanted defibrillator， 2 . Cerebrovascular disorder within 6 month prior screen examination ( asymptomatic cerebral infarction ) ， 3 . A history hypersensitivity idiosyncratic reaction benzazepine derivative mozavaptan hydrochloride benazepril hydrochloride . 8 . Subjects severely obese [ body mass index ( BMI , body weight ( kg ) /height ( ) 2 ] exceed 35 ] 9 . Subjects systolic blood pressure decubitus position exceed 90 mmHg 10 . Subjects follow abnormal laboratory value : 1 . Total bilirubin &gt; 3.0 mg/dL , 2. serum creatinine &gt; 3.0 mg/dL , 3. serum sodium &gt; 147 mEq/L , 4. serum potassium &gt; 5.5 mEq/L 11 . Patients unable take oral medication 12 . Female subject pregnant , possibly pregnant , lactate , plan become pregnant study period 13 . Subjects receive investigational drug OPC41061 within 30 day prior screen examination 14 . Subjects otherwise judge investigator subinvestigator inappropriate inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Vasopressin antagonist , Cardiac Edema , Diuretics</keyword>
</DOC>